---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-119230"
form_type: "8-K/A"
ticker: "STAA"
cik: "0000718937"
company_name: "STAAR SURGICAL CO"
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:47:48.606599+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# STAAR Surgical reports Q3 net sales up 10% to $88.6M; revises 2024 regional growth assumptions

## Summary
- Net income of $10.0M ($0.20 EPS) vs $4.8M ($0.10 EPS) a year ago; adjusted EBITDA $16.2M.
- ICL sales $89.1M, up 10%; gross margin 77.3% vs 79.2% on lower production absorption.
- FY 2024 net sales outlook maintained at $340-345M; adjusted EBITDA ~$42M.
- Americas EVO ICL growth revised to 17% (was 15%); U.S. to 20% (was 25%); EMEA to 10% (was 6%).
- APAC growth cut to 5% (was 7%); China growth slashed to ~2% (was 10%); other APAC now 10-20% (was flat).

## SEC filing metadata
- accession: 0000950170-24-119230
- form_type: 8-K/A
- ticker: STAA
- cik: 0000718937
- company_name: STAAR SURGICAL CO
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/718937/000095017024119230/0000950170-24-119230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/718937/000095017024119230/staa-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-119230
- JSON: https://secwatch.observer/filing/0000950170-24-119230.json
- Plain text: https://secwatch.observer/filing/0000950170-24-119230.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.